Using IBC as a prototype pre-clinical model for elucidating the role of MET in aggressive cancer, we manipulated the levels of E-Cadherin via shRNA knockdown and over-expression of ZEB1, a known transcriptional repressor of E-Cadherin. Here, CDH1 is linked to cancer.